Gestational diabetes mellitus has no affect on prohepcidin and other iron status parameters in infants

Authors

  • Artur Słomka Department of Pathophysiology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland Head: Ewa Żekanowska, PhD, Associate professor
  • Paulina Giemza-Kucharska Department of Pathophysiology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland Head: Ewa Żekanowska, PhD, Associate professor
  • Ewa Żekanowska Department of Pathophysiology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland Head: Ewa Żekanowska, PhD, Associate professor
  • Piotr Korbal Department of Pathophysiology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland Head: Ewa Żekanowska, PhD, Associate professor; Department of Neonatology and Neonatal Intensive Care, Jan Biziel University Hospital No 2, Bydgoszcz, Poland Head: Piotr Korbal, MD, PhD

Keywords:

Iron, Prohepcidin, Gestational diabetes mellitus, Newborns

Abstract

Background: Hepcidin is a major iron regulatory protein. The aim of this pilot study was to determine hepcidin precursor – prohepcidin and iron metabolism parameters in serum cord blood of infants delivered by gestational diabetes mellitus mothers (GDM).

Materials and methods: The study group comprised 12 infants delivered by women diagnosed with GDM. The control group consisted of 18 full-term healthy infants. In the serum cord blood were measured: prohepcidin, ferritin and soluble transferrin receptor (sTfR).

Results: There are no significant differences in prohepcidin, ferritin and sTfR concentration in serum cord blood between infants delivered by GDM mothers and healthy infants.

Conclusion: Gestational diabetes mellitus has no affect on prohepcidin and other iron status parameters in infants.

Supporting Agencies

Project supported by the European Social Fund and the Polish Government within the Integrated Regional Development Operational Programme, the project ‘Scholarship for PhD Students 2008/2009 – ZPORR’ of Kuyavian - Pomeranian Voivodeship’.

Downloads

Download data is not yet available.

References

Round JA, Jacklin P, Fraser RB, Hughes RG, Mugglestone MA, Holt RI. Screening for gestational diabetes mellitus: cost-utility of different screening strategies based on a woman’s individual risk of disease. Diabetologia 2011;54:256-63.

Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest 2005;115: 485-491.

Svare JA, Hansen BB, Mlsted-Pedersen L. Perinatal complications in women with gestational diabetes mellitus. Acta Obstet Gynecol Scand 2001;80:899-904.

Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 2007;30:251-60.

Westgate JA, Lindsay RS, Beattie J, Pattison NS, Gamble G, Mildenhall LFJ, et al. Hyperinsulinemia in cord blood in mothers with type 2 diabetes and gestational diabetes mellitus in New Zealand. Diabetes Care 2006;29:1345-50.

Pettitt DJ, Baird HR, Aleck KA, Bennett PH, Knowler WC. Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy. N Engl J Med 1983;308:242-5.

Lee AJ, Hiscock RJ, Wein P, Walker SP, Permezel M. Gestational diabetes mellitus: clinical predictors and long-term risk of developing type 2 diabetes: a retrospective cohort study using survival analysis. Diabetes Care 2007;30:878-83.

Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.

Li Y, Yan H, Bai B, Zhang Q. Effect of iron status of pregnant women on ferroportin 1 expression in third-trimester placenta. Wei Sheng Yan Jiu 2008;37:335-8.

Li YQ, Yan H, Bai B. Change in iron transporter expression in human term placenta with different maternal iron status. Eur J Obstet Gynecol Reprod Biol 2008;140:48-54.

Lao TT, Tam KF. Maternal serum ferritin and gestational impaired glucose tolerance. Diabetes Care 1997;20:1368-9.

Lao TT, Chan PL, Tam KF. Gestational diabetes mellitus in the last trimester - a feature of maternal iron excess? Diabet Med 2001;18:218-23.

Lao TT, Ho LF. Impact of iron deficiency anemia on prevalence of gestational diabetes mellitus. Diabetes Care 2004;27:650-6.

Bo S, Menato G, Villois P, Gambino R, Cassader M, Cotrino I, et al. Iron supplementation and gestational diabetes in midpregnancy. Am J Obstet Gynecol 2009;201:1-6.

Ervasti M, Sankilampi U, Luukkonen S, Heinonen S, Punnonen K. Maternal pro-hepcidin at term correlates with cord blood pro-hepcidin at birth. Eur J Obstet Gynecol Reprod Biol 2009;147:161-5.

Chełchowska M, Swiatek E, Ambroszkiewicz J, Gajewska J, Laskowska-Klita T, Leibschang J. Concentrations of pro-hepcidin in serum of pregnant women and in umbilical cord blood. Ginekol Pol 2008;79:754-7.

Tiker F, Celik B, Tarcan A, Kilicdag H, Ozbek N, Gurakan B. Serum pro-hepcidin levels and relationships with iron parameters in healthy preterm and term newborns. Pediatr Hematol Oncol 2006;23:293-7.

Amarilyo G, Mimouni FB, Oren A, Ochshorn Y, Ballin A, Deutsch V, et al. Prohepcidin concentrations and erythroid progenitors in cord blood of appropriate versus small for gestational age neonates. J Perinatol 2010;30:396-8.

Balogh A, Szabó M, Kelen D, Bokodi G, Prechl J, Bösze S, et al. Prohepcidin levels during human perinatal adaptation. Pediatr Hematol Oncol 2007;24:361-8.

Downloads

Published

2012-03-30

How to Cite

Słomka, A., Giemza-Kucharska, P., Żekanowska, E., & Korbal, P. (2012). Gestational diabetes mellitus has no affect on prohepcidin and other iron status parameters in infants. European Journal of Clinical and Experimental Medicine, 10(1), 70–73. Retrieved from https://journals.ur.edu.pl/ejcem/article/view/12782

Issue

Vol. 10 No. 1 (2012): Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw

Section

ORIGINAL PAPERS

License

Copyright (c) 2012 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.